Strategy for pancreatic cancer uses engineered exosomes targeting mutated KRAS gene

Lei Zheng named executive director of Mays Cancer Center

Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.

July 12, 2024

Vol.50 No.28

Clinical Roundup

New 3D technique reveals precancerous pancreatic lesions

Researchers at the Johns Hopkins Kimmel Cancer Center’s Sol Goldman Pancreatic Cancer Research Center have developed a 3D genomic profiling technique to identify small precancerous lesions in the pancreas—called pancreatic intraepithelial neoplasias—that lead to one of the most aggressive, deadly pancreatic cancers.

June 21, 2024

Vol.50 No.25

In Brief

Fox Chase received a total of $20M from Marvin and Concetta Greenberg

Fox Chase Cancer Center received a gift of $10.8 million from the Estate of Concetta “Chet” Greenberg. This gift is the culmination of many years of support, bringing Greenberg’s total giving to nearly $20 million for pancreatic cancer research at Fox Chase.

June 14, 2024

Vol.50 No.24

Clinical Roundup

CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data

Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Studies detail molecular pathway that impacts pancreatic cancer progression and response to treatment

Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have established the most comprehensive molecular portrait of the workings of KRAS and how its activities impact pancreatic cancer outcomes.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Alligator Bioscience initiates phase I study of intratumoral mitazalimab in locally advanced pancreatic cancer

Alligator Bioscience has announced the initiation of a phase I clinical study (NCT06205849) to evaluate the safety and efficacy of mitazalimab (CD40 mAb agonist) injected intratumorally at the time of surgical irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer.

May 17, 2024

Vol.50 No.20

Strategy for pancreatic cancer uses engineered exosomes targeting mutated KRAS gene

YOU MAY BE INTERESTED IN

Lei Zheng named executive director of Mays Cancer Center

New 3D technique reveals precancerous pancreatic lesions

Fox Chase received a total of $20M from Marvin and Concetta Greenberg

CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data

Studies detail molecular pathway that impacts pancreatic cancer progression and response to treatment

Alligator Bioscience initiates phase I study of intratumoral mitazalimab in locally advanced pancreatic cancer

Renew today!

Subscriber content

Login